IntraLuminal completes $20 million financing:
This article was originally published in Clinica
Executive Summary
IntraLuminal, which is developing products for the crossing and recanalisation of total occlusions, has completed the first tranche of a two-stage financing round. $20m is available immediately, with a further $10m triggered by milestones. The funds will be used for a continued rollout of the Carlsbad, California-based company's Safe-Cross TO crossing system, the selected introduction of the first generation SafeSteer system in the US and development of the second and next generation systems. Of the 4.3 million coronary artery patients worldwide undergoing coronary and peripheral diagnostic procedures annually, 1.2m will have one or more total occlusions, IntraLuminal says.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.